Who makes CoFactor and 5FU?

CoFactor and 5FU is developed by Mast Therapeutics, Inc..

What development phase is CoFactor and 5FU in?

CoFactor and 5FU is in Phase 2.

Last reviewed 2026-04-19 · How we verify

CoFactor and 5FU

Mast Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	CoFactor and 5FU
Sponsor	Mast Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) (PHASE2)
Clinical Trial in Patients With Metastatic Colorectal Cancer (PHASE2)
5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients (PHASE2)
Clinical Trial in Patients With Metastatic Colorectal Cancer (PHASE2)
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CoFactor and 5FU CI brief — competitive landscape report
CoFactor and 5FU updates RSS · CI watch RSS
Mast Therapeutics, Inc. portfolio CI